Literature DB >> 19070914

Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process.

Bruno Gagliardo1, Nicole Kubat, Audrey Faye, Maryse Jaouen, Béatrice Durel, Jean-Christophe Deschemin, François Canonne-Hergaux, Marie-Agnès Sari, Sophie Vaulont.   

Abstract

BACKGROUND/AIMS: The iron-regulatory peptide hepcidin is synthesized in the liver as an 84-aa pre-pro-hormone maturated by proteolysis through a consensus furin cleavage site to generate the bioactive 25-aa peptide secreted in the circulation. This peptide regulates iron export from enterocytes and macrophages by binding the membrane iron exporter, ferroportin, leading to its degradation. Whether pro-hepcidin could be secreted and reflect hepcidin levels remains an open question. However, the activity of the pro-peptide on ferroportin degradation has never been addressed.
METHODS: To answer this question, we produced recombinant pro-hepcidin, both the wild-type form and a furin cleavage site mutant, and tested their activity on ferroportin levels in macrophagic J774 cells. Furin activity was also modulated using furin inhibitor or siRNA-mediated furin mRNA knockdown.
RESULTS: We found that pro-hepcidin could fully induce ferroportin degradation, but only when processed by furin to generate the mature hepcidin-25 form. Pro-hepcidin activity was abolished in the presence of furin inhibitor and diminished after siRNA-mediated knockdown of furin mRNA. Furthermore, the mutated version of pro-hepcidin was completely inefficient at degrading ferroportin in macrophages.
CONCLUSIONS: Our results demonstrate that pro-hepcidin lacks biological activity, unless fully maturated by a furin-dependent process to yield the bioactive 25-aa peptide.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19070914     DOI: 10.1016/j.jhep.2008.09.018

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

Review 1.  Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD.

Authors:  Jodie L Babitt; Herbert Y Lin
Journal:  Am J Kidney Dis       Date:  2010-02-26       Impact factor: 8.860

2.  Buffalo hepcidin: characterization of cDNA and study of antimicrobial property.

Authors:  Victoria Chanu Khangembam; Ashok Kumar
Journal:  Vet Res Commun       Date:  2010-12-14       Impact factor: 2.459

Review 3.  Expression and function of iron-regulatory proteins in retina.

Authors:  Jaya P Gnana-Prakasam; Pamela M Martin; Sylvia B Smith; Vadivel Ganapathy
Journal:  IUBMB Life       Date:  2010-05       Impact factor: 3.885

4.  Hepcidin targets ferroportin for degradation in hepatocytes.

Authors:  Guillemette Ramey; Jean-Christophe Deschemin; Béatrice Durel; François Canonne-Hergaux; Gaël Nicolas; Sophie Vaulont
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

Review 5.  Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology.

Authors:  Driton Vela
Journal:  Lab Invest       Date:  2017-10-23       Impact factor: 5.662

Review 6.  Anemia in Chronic obstructive pulmonary disease: Prevalence, pathogenesis, and potential impact.

Authors:  Malay Sarkar; Puja Negi Rajta; Jasmin Khatana
Journal:  Lung India       Date:  2015 Mar-Apr

7.  Expression and cellular localization of hepcidin mRNA and protein in normal rat brain.

Authors:  Ruma Raha-Chowdhury; Animesh Alexander Raha; Serhiy Forostyak; Jing-Wei Zhao; Simon Russell William Stott; Adrian Bomford
Journal:  BMC Neurosci       Date:  2015-04-21       Impact factor: 3.288

8.  Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias.

Authors:  Elizabeta Nemeth
Journal:  Adv Hematol       Date:  2009-12-24

Review 9.  Mouse Models of Human Proprotein Convertase Insufficiency.

Authors:  Manita Shakya; Iris Lindberg
Journal:  Endocr Rev       Date:  2021-05-25       Impact factor: 19.871

Review 10.  Iron metabolism: current facts and future directions.

Authors:  Leida Tandara; Ilza Salamunic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.